Vor Biopharma Inc. (VOR) Form 424B5 — Oct 30, 2026
Vor Biopharma entered into a $150 million at-the-market offering agreement with William Blair and RBC Capital Markets dated October 30, 2026, replacing its prior $125 million Stifel ATM which was fully utilized and expired. Sales under the program are discretionary at prevailing market prices, with the agents earning up to a 3.0% commission. At the October 29, 2026 close of $20.91, full utilization would imply roughly 7.17 million new shares, lifting shares outstanding from about 61.4 million to about 68.6 million. The filing discloses a net tangible book value deficit of $137.2 million as of September 30, 2026 and immediate dilution of $20.79 per share to new investors at the assumed price.
Key figures
- Gross Proceeds
- 150000000
- Offering Price
- 20.91
- Shares Offered
- up to 7,173,601 shares at $20.91 (illustrative full utilization)
- Shares Outstanding
- 61429555
- Commission Rate
- up to 3.0% of gross sales price
- Offering Expenses
- 225000
- Shares Under Warrants
- 34664213
- Immediate Dilution Per Share
- 20.79
- Adjusted Net Tangible Book Value Per Share
- 0.12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.